1. Patient subjective visual function after corneal collagen crosslinking for keratoconus and corneal ectasia
- Author
-
Brooks, Nneka O., Greenstein, Steven, Fry, Kristen, and Hersh, Peter S.
- Subjects
- *
CORNEA diseases , *KERATOCONUS , *VISUAL acuity , *VISUAL perception , *COLLAGEN , *MEDICAL statistics , *CLINICAL trials , *QUESTIONNAIRES - Abstract
Purpose: To assess subjective visual function after corneal collagen crosslinking (CXL). Setting: Cornea and refractive surgery subspecialty practice. Design: Prospective randomized controlled clinical trial. Methods: Patients completed a subjective questionnaire regarding visual symptoms administered preoperatively and 1 year after CXL. Patients ranked self-reported symptoms of photophobia, difficulty night driving, difficulty reading, diplopia, fluctuations in vision, glare, halo, starburst, dryness, pain, and foreign-body sensation on a scale from 1 to 5. Possible associations of symptoms with changes in corrected distance visual acuity (CDVA) and maximum keratometry were also analyzed. Results: One hundred seven eyes of 76 patients had CXL for keratoconus (n = 71) or ectasia (n = 36). The mean preoperative to 1-year postoperative changes in night driving (3.2 ± 1.5 [SD] to 2.8 ± 1.5), difficulty reading (3.1 ± 1.5 to 2.9 ± 1.3), diplopia (2.5 ± 1.3 to 2.1 ± 1.2), glare (3.1 ± 1.4 to 2.7 ± 1.2), halo (2.9 ± 1.4 to 2.5 ± 1.3), starbursts (2.6 ± 1.5 to 2.4 ± 1.4), and foreign-body sensation (1.8 ± 1.1 to 1.6 ± 0.9) were statistically significant. There were no associations between the change in any symptom and changes in CDVA. There was a weak association between the change in night driving, pain, and foreign-body sensations and the change in maximum keratometry. Conclusions: After CXL, patients noted subjective improvement in visual symptoms, specifically night driving, difficulty reading, diplopia, glare, halo, starbursts, and foreign-body sensation. These subjective outcomes corroborate quantitative clinical improvements seen after CXL. Financial Disclosure: Dr. Hersh is medical monitor for Avedro, Inc. No author has a financial or proprietary interest in any material or method mentioned. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF